AlphaRX ANNOUNCES RESULTS ON HIGHLY EFFECTIVE, NOVEL, TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY FORMULATIONS
AlphaRX ANNOUNCES RESULTS ON HIGHLY EFFECTIVE, NOVEL, TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY FORMULATIONS
(PRWEB) May 16, 2002
AlphaRX ANNOUNCES RESULTS ON HIGHLY EFFECTIVE, NOVEL, TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY FORMULATIONS
AlphaRx (ALRX:OTCBB) is pleased to announce data and results on its new topical drug delivery formulation, as compiled by AlphaRxÂ’s Chief Scientist Joseph Schwarz, Ph. D. and Dr. Peter Carlen, senior scientist with the Toronto Western Research Institute, neurologist with the Krembil Neuroscience Centre at the Toronto Western Hospital, and professor of medicine (neurology) at the University Of Toronto.
The experimental design was repeated and the results were consistently reproducible in comparing a number of formulations using AlphRxÂ’s drug delivery formulation with some well-known commercial topical anti-inflammatory creams. The data supported the conclusion that AlphaRxÂ’s new topical formulations possess enhanced anti-inflammatory activity when compared to well-known commercial brands currently in the market. The research was conducted in the laboratories of Dr. Carlen, under a Sponsored Research Agreement between NeuroProtection Inc. (NPI) and the University Health Network (UHN).
AlphaRx has engaged NeuroProtection Inc. in a Research and Consulting Agreement under which NPI is designing a pre-clinical development program and clinical development strategy for AlphaRxÂ’s proprietary drug delivery system. NPI is conducting in-vivo investigations of compounds for enhanced delivery for site inflammation, brain inflammation, aging and neuroprotection. Some of the research is implemented via NPIÂ’s Sponsored Research Agreement with the University Health Network. The investigational compounds include Alpha RxÂ’s proprietary BCD drug delivery system in combination with standard Non-Steroidal Anti-inflammatory Drugs (NSAIDS). On-going work will include additional investigations with these compounds and with NeuroProtection Inc.Â’s proprietary MPCB neuro-protective agents.
The study demonstrated that AlphaRx’s new topical formulations, comprised of safe, well known delivery components, are stable, with low-irritancy, possess a high efficacy in the local delivery of biologically active compounds. Comparative anti-inflammatory activity of topical formulations included ARX cream (16% MeSal), Ben Gay™ “extraforte” cream (30% MeSal), Voltaren Emugel™, ARX cream (6-MC). The proprietary formulations can be readily manufactured with available industry-standard pharmaceutical equipment.
AlphaRx ‘s topical drug delivery formulation, utilizes natural and safe carrier components. This drug delivery vehicle significantly increases drug loading through a unique combination of polarity and hydrophobicity of the carrier components (US Patent pending). Additional refinements in this field by AlphaRx have resulted in the capability of formulating stable submicron emulsions without the use of high-pressure homogenizers (US Patent pending). Such “self-emulsifying” formulations containing Non-Steroidal Anti-inflammatory Drugs (NSAIDs) have been tested in non-infection, inflammatory animal models, in order to compare the relative activity of these drugs in traditional versus enhanced delivery vehicles. These in-vivo experiments have been carried out at the Toronto Western Hospital/University Health Network. The experimental protocol was peer reviewed and approved by the ethics review committee.
The experimental results are consistent and reproducible, supporting the suggestion that AlphaRx’s new topical formulations possess superior anti - inflammatory activity. For example, AlphaRx’s ARX cream with 16% Methylsalicylate produced a three-fold reduction in edema volume at peak activity, when compared to Pfizer’s well-known and popular BenGay™ “Extra Forte” OTC cream (30% Methylsalicylate). All AlphaRx compositions showed similar enhanced anti-inflammatory activity when compared to other test formulations.
*Data was prepared Q-1 2002.
About AlphaRx
AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of carefully selected, currently marketed drugs, which, through the application of its proprietary BCD drug delivery technology, offer improved medical benefits over existing products with a strong commercial potential.
About UHN
University Health Network is a major landmark in Canada's health care system and a teaching hospital of the University of Toronto. Building on the strengths and reputation of each of three remarkable hospitals, Toronto Western Hospital, Toronto General Hospital, and Princess Margaret Hospital, the organization brings together the talent and resources that make it an international leader in health care.
About NeuroProtection Inc.
NeuroProtection Inc. is a Toronto-based R&D company actively engaged in the discovery and development of novel agents for development as pharmaceuticals with neuroprotective applications. The company houses several patents and patent applications covering its proprietary MPCB technology for neuroprotection and has other Intellectual Property in process.
Contact:
AlphaRx http://www. alpharx. com (http://www. alpharx. com) Michael M. Lee Tel: 905-762-0745 Ext 101
NeuroProtection Inc. Craig Sibley Tel 416-450-8231E-mail presciencedev@rogers. com
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
Econ Investor Relations ConnieLinder Toll free: 888-368-8705 Email: clinder@investorideas. com
